Johnson & Johnson 以3.05B美元购买Halda治疗药物,以推进口服癌症药物HLD-0915。 Johnson & Johnson to buy Halda Therapeutics for $3.05B to advance oral cancer drug HLD-0915.

Johnson & Johnson同意以30.5亿美元的现金购买生物技术Halda治疗药物,以支持其肿瘤管道,重点是针对固体肿瘤的口服定向治疗。 Johnson & Johnson agreed to acquire biotech Halda Therapeutics for $3.05 billion in cash to bolster its oncology pipeline, focusing on oral, targeted therapies for solid tumors. 以哈尔达的主要候选人HLD-0915为交易中心,这是一种口服前列腺癌治疗,以FDA快车道命名,旨在克服治疗阻力。 The deal centers on Halda’s lead candidate, HLD-0915, an oral prostate cancer treatment with FDA Fast Track designation, designed to overcome treatment resistance. 这项收购预计将在2026年初完成,等待监管批准,它加强了J&J对精准医学的推动,并增加了对多种癌症的潜在新疗法。 The acquisition, expected to close in early 2026 pending regulatory approval, strengthens J&J’s push into precision medicine and adds a potential new therapy for multiple cancers. 这项交易将使J&J的2026年调整后的每股收入减少约15美分。 The transaction will reduce J&J’s 2026 adjusted earnings per share by about 15 cents.